NORTH CHICAGO, Ill., March 18, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of March 16, 2020 its issued share capital, excluding treasury shares, is comprised of 1,476,672,808 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on March 16, 2020, there were outstanding 8,299,655 options to purchase shares of common stock (the "Stock Options"), 8,008,786 restricted stock units (the "Restricted Stock Units") and 2,714,203 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-301025777.html

SOURCE AbbVie

NORTH CHICAGO, Ill., March 4, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of March 2, 2020 its issued share capital, excluding treasury shares, is comprised of 1,482,464,688 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on March 2, 2020, there were outstanding 6,306,351 options to purchase shares of common stock (the "Stock Options"), 4,314,754 restricted stock units (the "Restricted Stock Units") and 1,654,154 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-301015828.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Feb. 25, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 21, 2020 its issued share capital, excluding treasury shares, is comprised of 1,481,908,359 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on February 21, 2020, there were outstanding 6,309,351 options to purchase shares of common stock (the "Stock Options"), 4,322,250 restricted stock units (the "Restricted Stock Units") and 2,395,554 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-301010329.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Feb. 19, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 17, 2020 its issued share capital, excluding treasury shares, is comprised of 1,479,512,883 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on February 17, 2020, there were outstanding 6,341,615 options to purchase shares of common stock (the "Stock Options"), 5,669,845 restricted stock units (the "Restricted Stock Units") and 2,395,554 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-301007194.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Feb. 5, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of February 3, 2020 its issued share capital, excluding treasury shares, is comprised of 1,479,156,683 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on February 3, 2020, there were outstanding 6,489,244 options to purchase shares of common stock (the "Stock Options"), 7,785,282 restricted stock units (the "Restricted Stock Units") and 2,395,554 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300998979.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Jan. 22, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of January 20, 2020 its issued share capital, excluding treasury shares, is comprised of 1,479,155,708 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on January 20, 2020, there were outstanding 6,493,592 options to purchase shares of common stock (the "Stock Options"), 7,782,283 restricted stock units (the "Restricted Stock Units") and 2,398,082 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300990854.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Jan. 8, 2020 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of January 6, 2020 its issued share capital, excluding treasury shares, is comprised of 1,478,912,545 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on January 6, 2020, there were outstanding 6,732,365 options to purchase shares of common stock (the "Stock Options"), 7,794,531 restricted stock units (the "Restricted Stock Units") and 2,399,662 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300983178.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Dec. 20, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of December 18, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,875,921 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on December 18, 2019, there were outstanding 6,763,995 options to purchase shares of common stock (the "Stock Options"), 7,825,750 restricted stock units (the "Restricted Stock Units") and 2,405,478 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300978118.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Dec. 11, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of December 9, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,867,665 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on December 9, 2019, there were outstanding 6,765,145 options to purchase shares of common stock (the "Stock Options"), 7,823,032 restricted stock units (the "Restricted Stock Units") and 2,405,478 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300973199.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Nov. 27, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 25, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,862,394 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on November 25, 2019, there were outstanding 6,770,092 options to purchase shares of common stock (the "Stock Options"), 7,858,656 restricted stock units (the "Restricted Stock Units") and 2,410,155 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300965891.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Nov. 13, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 11, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,830,254 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on November 11, 2019, there were outstanding 6,791,458 options to purchase shares of common stock (the "Stock Options"), 7,876,529 restricted stock units (the "Restricted Stock Units") and 2,412,498 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300957067.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Nov. 8, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 6, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,830,254 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on November 6, 2019, there were outstanding 6,802,233 options to purchase shares of common stock (the "Stock Options"), 7,884,864 restricted stock units (the "Restricted Stock Units") and 2,413,956 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300954435.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Oct. 30, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of October 28, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,821,109 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on October 28, 2019, there were outstanding 6,820,038 options to purchase shares of common stock (the "Stock Options"), 7,832,441 restricted stock units (the "Restricted Stock Units") and 2,380,761 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300947782.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Oct. 16, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of October 14, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,820,152 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV. The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on October 14, 2019, there were outstanding 6,820,995 options to purchase shares of common stock (the "Stock Options"), 7,840,751 restricted stock units (the "Restricted Stock Units") and 2,380,761 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300939284.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Oct. 2, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 30, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,782,106 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on September 30, 2019, there were outstanding 6,823,172 options to purchase shares of common stock (the "Stock Options"), 7,924,311 restricted stock units (the "Restricted Stock Units") and 2,384,869 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300929257.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Sept. 18, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 16, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,779,037 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on September 16, 2019, there were outstanding 6,826,241 options to purchase shares of common stock (the "Stock Options"), 7,947,357 restricted stock units (the "Restricted Stock Units") and 2,386,702 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300920500.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Sept. 4, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of September 2, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,773,465 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on September 2, 2019, there were outstanding 6,827,640 options to purchase shares of common stock (the "Stock Options"), 7,965,451 restricted stock units (the "Restricted Stock Units") and 2,388,282 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300911212.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Aug. 21, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of August 19, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,768,075 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on August 19, 2019, there were outstanding 6,833,593 options to purchase shares of common stock (the "Stock Options"), 7,983,468 restricted stock units (the "Restricted Stock Units") and 2,394,287 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300904791.html

SOURCE AbbVie

NORTH CHICAGO, Ill., Aug. 7, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of August 5, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,483,918 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on August 5, 2019, there were outstanding 6,837,308 options to purchase shares of common stock (the "Stock Options"), 8,020,475 restricted stock units (the "Restricted Stock Units") and 2,398,459 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300897610.html

SOURCE AbbVie

NORTH CHICAGO, Ill., July 24, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of July 22, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,481,177 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on July 22, 2019, there were outstanding 6,839,586 options to purchase shares of common stock (the "Stock Options"), 7,968,197 restricted stock units (the "Restricted Stock Units") and 2,388,508 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300890043.html

SOURCE AbbVie

NORTH CHICAGO, Ill., July 10, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of July 8, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,373,039 shares of common stock with a par value of $0.01 per share. AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.  The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.

AbbVie confirms that, as of the close of business on July 8, 2019, there were outstanding 6,840,085 options to purchase shares of common stock (the "Stock Options"), 7,986,251 restricted stock units (the "Restricted Stock Units") and 2,392,617 performance shares (the "Performance Shares"). Upon exercise, each Stock Option entitles the holder to purchase one share of common stock at the applicable exercise price. Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.

The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---rule-2-10-announcement---relevant-securities-in-issue-300882147.html

SOURCE AbbVie